GlassScriptPhysician profile
Johnny Ray Herrera
NPI 1609646918
$6,586.61
in general payments reported to CMS, 2019-2025
35 companies · $4,420 in 2025
The $4,420 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,167 · 2025: $4,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,471 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,470.62 |
| Education | $115.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.13 | 2024-2025 | |
| Argenx US, INC. | $471.41 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $451.53 | 2024-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $436.73 | 2024-2025 | |
| Ucb, INC. | $415.96 | 2024-2025 | Fintepla, Nayzilam, Briviact |
| Harmony Biosciences LLC | $347.32 | 2024-2025 | |
| Pfizer INC. | $303.61 | 2024-2025 | |
| Neurelis, INC. | $255.10 | 2024-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $250.66 | 2024-2025 | Spravato |
| Lilly USA, LLC | $249.53 | 2024-2025 | Kisunla, Zepbound, Amyvid |
| Sk Life Science, INC. | $248.01 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $202.54 | 2024-2025 | |
| Axsome Therapeutics, INC. | $194.53 | 2024-2025 | Sunosi |
| Lundbeck LLC | $187.50 | 2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $185.07 | 2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $160.46 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $149.30 | 2025 | |
| Biogen, INC. | $141.23 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Genentech, INC. | $128.29 | 2025 | Ocrevus |
| Ani Pharmaceuticals, INC. | $125.01 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Hyqvia |
| Genentech USA, INC. | $124.88 | 2024-2025 | Ocrevus Zunovo |
| Ipsen Biopharmaceuticals, INC | $124.83 | 2025 | Dysport |
| Immedica Pharma US, INC. | $100.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $84.65 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $77.61 | 2025 | |
| Ge Healthcare | $49.16 | 2024-2025 | |
| Janssen Biotech, INC. | $39.92 | 2025 | |
| Banner Life Sciences, LLC | $37.13 | 2024 | |
| Vanda Pharmaceuticals INC. | $34.57 | 2025 | Ponvory |
| Eisai INC. | $31.84 | 2024 | |
| Merz Pharmaceuticals, LLC | $20.65 | 2025 | Xeomin |
| Grifols USA, LLC | $16.83 | 2024 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $14.02 | 2025 | Ongentys |
| Teva Pharmaceuticals USA, INC. | $13.60 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.